HROW - stevehemingway/trading GitHub Wiki

Bonitas Research published on Harrow Health Inc (NASDAQ: HROW — $502 million), a pharmaceutical company focused on products related to eye surgeries. Bonitas called the company “an unprofitable stock promotion neglecting risk disclosures and quality control standards.” Specifically, Bonitas highlighted an August 2022 Department of Justice subpoena concerning the company’s sales and marketing, a June 2022 FDA Warning Letter concerning false and misleading marketing claims, and an August 2022 FDA Form 483 inspection report concerning unsanitary drug manufacturing conditions. Bonitas concluded,

“With significant liabilities managed by bad actors willing to enrich themselves at the expense of minority HROW shareholders, we are short Harrow and think its stock is going lower.”